Mechanistic Elucidation of Class Switch Recombination and Somatic Hypermutation
- Institution
- SLOAN-KETTERING INST CAN RESEARCH, NY
- Principal investigator
- Jayanta Chaudhuri
- Funding
- $515K
- Duration
- 2009–2026
Moonbase score
Still being scored
Abstract
ABSTRACT Upon encountering antigens, mature B cells express activation induced cytidine deaminase (AID) and undergo immunoglobulin heavy chain (Igh) class switch recombination (CSR) and somatic hypermutation (SHM). CSR proceeds through the obligate generation of DNA double strand breaks (DSBs), which constitute one of the most toxic lesions that can occur in a cell. A single unrepaired DSB can cause cell death or potentiate chromosomal translocations that are hallmarks of many types of cancer, including lymphomas. Thus, mechanisms that promote generation of DSBs and facilitate DSB repair are intergral to both immunity and preservation of genomic integrity. In this proposal we test the notion that single proteins can coordinate both DSB formation and mediate end-joining to efficiently generate and repair DSBs. We test the hypothesis that the nucleosomal remodeling protein CHD4 co-ordinates generation and repair of Igh DSBs (aim 1) and the C- terminus of AID mediates efficient DNA repair of Igh DSBs (aim 2). Successful completion of the experiments will have far reaching implications in our understanding of both B cell immunity and B cell lymphomas.
LOADING MOONBASE SCORE
Questions for SLOAN-KETTERING INST CAN RESEARCH
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Sloan-Kettering Inst Can ResearchNot yet scored
RNA-directed targeting of AID in immunity and cancer
Jayanta Chaudhuri · $531K · 2016–2027
- NIH · Sloan-Kettering Inst Can Research60
Expansion of Tumoroid Models for Precise Treatment of the Rectal Cancer Patient
Jesse Joshua Smith · $80K · 2025
- NIH · Sloan-Kettering Inst Can Research51
Phase II Study of ASTX727 in Patients with PRC2 loss Malignant Peripheral Nerve Sheath Tumor (MPNST)
Ping Chi · $576K · 2022–2026